[DOC] Healthpeak Properties Thesis 2026: Physicians Realty Merger Tests Lab and Medical Office Integration
Healthpeak Properties, Inc. (NYSE: DOC; ticker change Healthpeak → DOC March 2024 post-Physicians Realty merger reflecting medical theme; rebranded to Healthpeak Properties 2019 from Healthcare Properties Trust) FY2025 revenue ~$2.7-2.9B (+5-8%) with adj. EPS ~$0.45-0.75 (FFO per share ~$1.85-2.10) reflecting continued post-March 2024 Physicians Realty Trust $21B merger integration (~$50M+ cost synergies achieved + ~50M+ sq ft medical office portfolio) + selected post-2024 Lab segment biopharma R&D cycle weakness (similar to ARE) + selected ~5-year continuous dividend track post-2020 reset under continued CEO Scott Brinker (~3-year tenure since November 2022). Leading life science + medical office + senior housing REIT focused on healthcare real estate. Founded 1985 as Healthcare Properties Trust + selected various rebrands and corporate transformations through ~40-year history; current Healthpeak Properties formed 2019 rebrand; merged with Physicians Realty Trust March 1, 2024 ~$21B aggregate (creating selected largest US healthcare REIT). Headquartered in Denver Colorado; ~340+ employees globally with ~$2.7-2.9B revenue. Three reporting segments: Lab (life science) ~50% revenue ($1.4B — post-2020 ~$5B+ life science portfolio acquisitions; ~$11M+ sq ft; San Francisco Bay Area ~40% + Boston ~30% + Research Triangle + selected), Outpatient Medical (medical office) ~30% ($0.85B — post-March 2024 Physicians Realty Trust merger contribution; ~50M+ sq ft hospital-affiliated MOB + ambulatory surgery centers + ~340 medical office buildings), CCRC (continuing care retirement communities) ~20% ($0.55-0.65B — senior housing operating partnership with selected operators). March 2024 Physicians Realty $21B merger integration: March 1, 2024 closing of Healthpeak + Physicians Realty Trust all-stock merger; Healthpeak ~67% post-merger ownership + Physicians Realty ~33%; Physicians Realty contributed ~$0.85B revenue + ~50M+ sq ft medical office portfolio + ~340 medical office buildings; ~$50M+ annualized cost synergies achieved by FY2025; ticker change Healthpeak → DOC reflecting medical/healthcare theme; FY2026 catalyst: continued integration + operating margin expansion via overhead consolidation. Lab segment biopharma R&D cycle: post-2020 ~$5B+ life science portfolio acquisitions; ~$11M+ sq ft (San Francisco Bay Area + Boston + Research Triangle); post-2024 biopharma R&D cycle weakness affecting Lab occupancy (~85-90% vs ~95%+ historical; similar to ARE); biotech tenant downsizing + lease non-renewals (~30-40% biopharma R&D budget tightening); FY2026 catalyst: continued biopharma cycle stabilization + Lab occupancy recovery toward ~88-92%. CEO Scott M. Brinker since November 2022 (succeeded Tom Herzog CEO 2019-November 2022 retired who led 2019 Healthpeak rebrand + post-2020 life science pivot; Brinker ex-Hines Securities chief operating officer + ~25-year career). Capital return: ~$1.20-1.24 annual dividend FY2025 (~5-year track post-2020 dividend reset); modest buybacks; investment-grade Baa1/BBB+ credit ratings; FCF $0.5-0.7B. FY2026 thesis: Physicians Realty integration + Lab biopharma cycle recovery + ~6-year dividend track + Outpatient Medical stability. Risks: Lab biopharma R&D cycle continued weakness, Physicians Realty integration disruption, major CCRC operator distress, interest rate severe.
[DOC] Healthpeak Properties Thesis 2026: Physicians Realty Merger Tests Lab and Medical Office Integration
Key Takeaways
- March 2024 Physicians Realty $21B Integration: Selected March 1, 2024 closing of Healthpeak + Physicians Realty Trust all-stock merger ~$21B aggregate (selected creating largest US healthcare REIT); selected Healthpeak ~67% post-merger ownership + Physicians Realty ~33%; selected ~$50M+ annualized cost synergies achieved by FY2025; selected post-merger Outpatient Medical segment ~$0.85B revenue from Physicians Realty contribution.
- Lab Segment Biopharma R&D Cycle Weakness: Lab segment ~$1.4B FY2025 (~50% of total); selected ~$11M+ sq ft life science portfolio (San Francisco Bay Area + Boston + selected); selected post-2024 biopharma R&D cycle weakness affecting Lab segment occupancy (~85-90% vs ~95%+ historical; similar to ARE); FY2026 catalyst: continued biopharma R&D cycle stabilization + Lab occupancy recovery toward ~88-92%.
- Outpatient Medical Office Stability: Outpatient Medical segment ~$0.85B FY2025 (~30% of total; post-March 2024 Physicians Realty merger contribution); ~50M+ sq ft medical office portfolio (selected hospital-affiliated MOB + ambulatory surgery centers + selected); selected stable ~92-95% occupancy reflecting selected continued healthcare demand growth.
- Capital Return + 5-Year Dividend Track:
$1.20-1.24 annual dividend FY2025 ($0.30-0.31/quarter; ~5-year track post-2020 dividend reset); modest buybacks; investment-grade Baa1/BBB+ credit ratings; FCF $0.5-0.7B; FY2026 expected dividend toward $1.24-1.30 (+3-5%) maintaining ~6-year dividend track.
Company Background
Healthpeak Properties, Inc. (NYSE: DOC; rebranded to Healthpeak Properties 2019 from Healthcare Properties Trust + ticker change to DOC March 2024 post-Physicians Realty merger reflecting Doc/Medical theme) is the leading life science + medical office + senior housing REIT focused on healthcare real estate. Founded 1985 as Healthcare Properties Trust + selected various rebrands and corporate transformations through ~40-year history; current Healthpeak Properties formed 2019 rebrand; merged with Physicians Realty Trust March 2024 ~$21B aggregate creating selected largest US healthcare REIT.
Headquartered in Denver Colorado; ~340+ employees globally with FY2025 revenue ~$2.7-2.9B (+5-8% YoY) generating ~$300-500M net income (~10-17% net margin) and ~$0.45-0.75 EPS on 707M diluted shares ($1.85-2.10 FFO per share).
The company operates three reporting segments: Lab (life science) ~50% of revenue ($1.4B — selected post-2020 ~$5B+ life science portfolio acquisitions; ~$11M+ sq ft; selected San Francisco Bay Area + Boston + Research Triangle + selected); Outpatient Medical (medical office) ~30% ($0.85B — post-March 2024 Physicians Realty Trust merger contribution; selected ~50M+ sq ft hospital-affiliated MOB + ambulatory surgery centers); CCRC (continuing care retirement communities) ~20% ($0.55-0.65B — selected senior housing operating partnership with selected operators).
CEO Scott M. Brinker since November 2022 (~3-year tenure; succeeded Tom Herzog CEO 2019-November 2022 retired who led 2019 Healthpeak rebrand + selected post-2020 life science pivot; Brinker ex-Hines Securities chief operating officer + ex-various real estate roles + ~25-year career). Selected Brinker era characterized by: (i) selected post-2022 strategic refocus; (ii) selected March 2024 Physicians Realty $21B merger execution; (iii) selected continued life science + medical office + senior housing diversification.
March 2024 Physicians Realty $21B Merger Integration
Selected March 1, 2024 closing of Healthpeak + Physicians Realty Trust all-stock merger represents Healthpeak's largest transformative transaction. Selected key economics: (i) ~$21B aggregate enterprise value at merger; (ii) Healthpeak ~67% post-merger ownership + Physicians Realty ~33%; (iii) selected Physicians Realty contributed ~$0.85B revenue + ~50M+ sq ft medical office portfolio + ~340 medical office buildings; (iv) selected ~$50M+ annualized cost synergies achieved by FY2025; (v) selected post-merger ticker change Healthpeak → DOC reflecting medical/healthcare theme.
FY2026 catalyst: continued Physicians Realty integration + selected operating margin expansion via overhead consolidation + selected operational improvements. Material change rule: Physicians Realty integration costs above $100M annualized (severe integration challenges) OR major Outpatient Medical occupancy declines below 90%.
Lab Segment Biopharma R&D Cycle
Lab segment ~$1.4B FY2025 (~50% of total) reflects: (i) selected ~$11M+ sq ft life science portfolio (San Francisco Bay Area ~40% + Boston ~30% + Research Triangle + selected); (ii) selected post-2020 ~$5B+ life science portfolio acquisitions; (iii) selected post-2024 biopharma R&D cycle weakness affecting Lab occupancy (~85-90% vs ~95%+ historical; similar to ARE); (iv) selected biotech tenant downsizing + lease non-renewals (~30-40% biopharma R&D budget tightening).
FY2026 catalyst: continued biopharma R&D cycle stabilization + Lab occupancy recovery toward ~88-92%; selected new biotech tenant onboarding; selected continued cluster premium pricing.
Outpatient Medical + CCRC Diversification
Outpatient Medical ~$0.85B FY2025 (~30%) reflects selected ~50M+ sq ft medical office portfolio (hospital-affiliated MOB + ambulatory surgery centers); selected ~92-95% stable occupancy. CCRC ~$0.55-0.65B (~20%) reflects selected senior housing operating partnership with selected operators.
Key Core Metrics
| Metric | FY2022 | FY2023 | FY2024 (post-merger H2) | FY2025E | FY2026E |
|---|---|---|---|---|---|
| Total Revenue | $2.04B | $2.13B | $2.65B | $2.7-2.9B | $2.8-3.0B |
| Lab | $1.0B | $1.2B | $1.4B | $1.4B | $1.4-1.5B |
| Outpatient Medical | $0.6B | $0.6B | $0.7B (Q2-Q4 post-merger) | $0.85B | $0.85-0.95B |
| CCRC | $0.4B | $0.4B | $0.55B | $0.55-0.65B | $0.55-0.65B |
| FFO per Share | $1.83 | $1.78 | $1.81 | $1.85-2.10 | $1.95-2.20 |
| Adj. EPS | $0.40 | $0.45 | $0.55 | $0.45-0.75 | $0.55-0.85 |
| FCF | $0.5B | $0.5B | $0.6B | $0.5-0.7B | $0.6-0.8B |
| Capital Return | FY2024 | FY2025E | FY2026E |
|---|---|---|---|
| Dividend per Share | $1.20 | $1.20-1.24 | $1.24-1.30 |
| Dividend Continuous Years | ~4 (post-2020 reset) | ~5 | ~6 |
| Buybacks | $0 | $0 | $0 |
| Total Capital Return | $850M | $850M-880M | $880M-920M |
| Credit Rating | Baa1/BBB+ | Baa1/BBB+ | Baa1/BBB+ |
Market Evaluation
DOC currently trades at ~10-13x FFO reflecting: (i) selected post-March 2024 Physicians Realty merger optionality; (ii) selected diversified life science + medical office + senior housing portfolio; (iii) selected ~5-year continuous dividend track post-2020 reset; (iv) selected investment-grade Baa1/BBB+ credit; offset by (v) selected biopharma R&D cycle weakness affecting Lab; (vi) selected post-2020 dividend reset shorter track record vs peers.
Selected peer comparison: Alexandria Real Estate (ARE ~10-13x FFO life science pure-play), Ventas (VTR ~12-15x FFO senior housing + medical), Welltower (WELL ~17-22x FFO senior housing + medical premium), Boston Properties (BXP ~9-12x FFO Class A office). DOC valuation reflects diversified healthcare REIT positioning with selected Physicians Realty merger optionality.
FY2026 catalysts: (i) Physicians Realty integration completion; (ii) Lab biopharma cycle recovery; (iii) ~6-year dividend track; (iv) Outpatient Medical stability. Risks: (i) Lab biopharma R&D cycle continued weakness; (ii) Physicians Realty integration disruption; (iii) major CCRC operator distress; (iv) interest rate severe.
Physicians Realty Integration and Healthcare Diversification
The FY2026 thesis hinges on Healthpeak's ability to complete Physicians Realty $21B merger integration + capture biopharma R&D cycle stabilization + sustain ~6-year dividend track post-2020 reset. Physicians Realty integration completion supports continued Outpatient Medical operational improvements + selected ~$50M+ cost synergies.
Total revenue $2.8-3.0B FY2026 (+3-5%) + FFO per share $1.95-2.20 reflects selected biopharma R&D cycle recovery + Physicians Realty integration + selected operational excellence.
Material risks: (i) Lab biopharma R&D cycle continued weakness; (ii) Physicians Realty integration costs above $100M annualized; (iii) major CCRC operator distress; (iv) interest rate severe.
FY2026-2027 base case: revenue $2.8-3.0B (+3-5%) + $2.9-3.1B (+3-5%); FFO per share $1.95-2.20 + $2.05-2.35; Lab $1.4-1.5B + $1.5-1.6B; capital return $880M-920M + $920M-960M; dividend $1.24-1.30 + $1.28-1.35 maintaining 6-7 consecutive year dividend track post-2020 reset. Selected diversified healthcare REIT franchise + selected Physicians Realty merger optionality + selected continued dividend continuity support continued strategic positioning through FY2027.
